| Nov 3 |
Supernus Pharmaceuticals Q3 2024 Earnings Preview
|
| Oct 31 |
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
|
| Oct 21 |
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
|
| Oct 19 |
Supernus’ depression drug improved symptoms in two hours in Phase IIa study
|
| Oct 17 |
Supernus Pharmaceuticals Reports 'Promising' Data in Trial of Anti-Depression Drug Candidate
|
| Oct 17 |
Supernus reports Phase 2a data for SPN-820, stock climbs 6%
|
| Oct 17 |
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
|
| Oct 10 |
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
|
| Oct 9 |
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Sep 24 |
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
|
